MAPK3 and B-cell chronic lymphocytic leukemia: Ulixertinib (BVD-523), a potent and highly selective ERK1/2 inhibitor, was shown to inhibit ERK phosphorylation in vitro across all CLL cases harboring mutations in genes of the RAS-BRAF-MAPK-ERK pathway [38].